https://orcid.org/0000-0002-2391-2462
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Adoptive cell therapy (ACT) is a promising treatment that is considered safe and efficient. Natural killer (NK) cells play an important role in the innate immune system and destroy target cells such as tumor cells without prior sensitization. Here, we report a 59-year-old man with advanced diffuse hepatocellular carcinoma (HCC) who underwent 17 courses of NK cell treatment from March 2017 to July 2018. Although he presented with progressive disease, his hydrothorax and ascites decreased, and his state of mind, appetite and quality of life were markedly improved after treatment versus at admission. To date, his survival time is >48 months. Here, we provide evidence that NK cell adoptive therapy has no adverse effects, enhances immune function, and improves the quality of life of patients with HCC.
Ethics Approval and Consent to Participate
This study was approved by The Third Affiliated Hospital of Shenzhen University (IRB ID: 20160817, 2018LHYYZLNK-006-01). The patient provided written informed consent according to the Declaration of Helsinki.
Consent for Publication
The patient provided written informed consent for the case details to be published.
Acknowledgments
The authors would like to thank all members of the study team, the patient and his family.
Disclosure
The authors report no conflicts of interest in this work.